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Net benefit approaches to the evaluation of prediction models, 
molecular markers, and diagnostic tests
Andrew J Vickers,1 Ben Van Calster,2,3 Ewout W Steyerberg3 
Many decisions in medicine involve 
trade-offs, such as between diagnosing 
patients with disease versus 
unnecessary additional testing for 
those who are healthy. Net benefit is an 
increasingly reported decision analytic 
measure that puts benefits and harms 
on the same scale. This is achieved by 
specifying an exchange rate, a clinical 
judgment of the relative value of 
benefits (such as detecting a cancer) 
and harms (such as unnecessary 
biopsy) associated with models, 
markers, and tests. The exchange rate 
can be derived by asking simple 
questions, such as the maximum 
number of patients a doctor would 
recommend for biopsy to find one 
cancer. As the answers to these sorts of 
questions are subjective, it is possible 
to plot net benefit for a range of 
reasonable exchange rates in a 
“decision curve.” For clinical prediction 
models, the exchange rate is related to 
the probability threshold to determine 
whether a patient is classified as being 
positive or negative for a disease. Net 
benefit is useful for determining 
whether basing clinical decisions on a 
model, marker, or test would do more 
good than harm. This is in contrast to 
traditional measures such as 
sensitivity, specificity, or area under the 
curve, which are statistical abstractions 
not directly informative about clinical 
value. Recent years have seen an 
increase in practical applications of net 
benefit analysis to research data. This 
is a welcome development, since 
decision analytic techniques are of 
particular value when the purpose of a 
model, marker, or test is to help 
doctors make better clinical decisions.
Decision making and net benefit
Traditional statistical measures for the evaluation of 
prediction models, markers, and tests include sensitiv-
ity, specificity, area under the curve, and calibration.1 
Such measures do not, however, provide an answer as 
to whether the model, marker, or test should be used in 
clinical practice. For instance, it is not clear how high 
the sensitivity, specificity, or area under the curve needs 
to be to warrant clinical use. It is similarly unclear what 
degree of miscalibration would suggest that a predic-
tion model should not be used, or how to chose between 
two models, one with better calibration and the other 
with better discrimination.
Decision analysis attempts to tackle such problems by 
incorporating the clinical consequences of using a 
model, marker, or test. A key concept in decision analy-
sis is the idea of a trade-off between different endpoints. 
An obvious example of a trade-off is when a treatment 
helps reduce one symptom, such as heartburn, but 
causes a quite different symptom, such as dry mouth, as 
a side effect. Diagnostic tests are subject to a similar 
problem: a test may lead to early identification and 
curative treatment in patients with a disease that has 
been correctly diagnosed, but unless specificity is 
100%, some patients without disease will be subject to 
unnecessary further diagnostic work-up and 
 interventions. This problem of trade-off makes it diffi-
cult to evaluate tests. For instance, imagine a test for 
cancer that led to biopsy in 25 patients with disease but 
also in 75 patients who were cancer-free. If a new test 
Summary pointS
Prediction models, diagnostic tests, and molecular markers are traditionally 
evaluated using statistics such as sensitivity and specificity; such statistics do not 
tell us whether the model, test, or marker would do more good than harm if used in 
clinical practice
Decision analysis attempts to assess clinical value by incorporating clinical 
consequences, such as the benefit of finding disease early or the harm of 
unnecessary further testing
Net benefit is a simple type of decision analysis in which harm is multiplied by an 
“exchange rate” to place it on the same scale as benefit
It is relatively straightforward to specify an exchange rate by asking about common 
medical practice; net benefit can also be plotted against a range of exchange rates 
in what is called a “decision curve”
Decision curves are now widely used in the literature to evaluate whether clinical 
use of prediction models, diagnostic tests, and molecular markers would do more 
good than harm
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reduces the number of unnecessary biopsies to 50, but 
only finds 22 cancers, we need to consider whether miss-
ing three cancers to avoid 25 biopsies is a good trade-off.
Net benefit is a simple type of decision analysis, with 
benefits and harms put on the same scale so that they 
can be compared directly. Net benefit is similar to the 
idea of net profit in business. Take the case of an 
importer who buys €1m of wine from France and sells it 
in the United States for $1.5m. To work out the profit, 
dollars and euros need to be on the same scale, using 
the currency exchange rate. If €1 is worth $1.25 then we 
calculate profit=income in dollars (1.5m)−expenditure 
in euros (1m)×1.25=$250 000. Net benefit applies a sim-
ilar methodology to medical research, by specifying an 
exchange rate between different medical endpoints, 
such as finding cancer versus unnecessary biopsy.
In this paper we explain the use of net benefit for the 
evaluation of prediction models, molecular markers, 
and diagnostic tests. Models, markers, and tests can be 
grouped together as forms of “risk prediction” and are 
subject to similar principles of research design and sta-
tistical analysis.
net benefit and risk prediction
To introduce the concept of net benefit in medical 
research, we use biopsy for prostate cancer as an exam-
ple. Men with elevated levels of prostate specific anti-
gen (PSA) are at increased risk of aggressive prostate 
cancer and often referred for biopsy of the prostate. But 
most men with high PSA levels have either no cancer or 
only low grade tumors, which do not need treatment.2 
Biopsy is not only invasive and unpleasant but can 
cause infection. Researchers have actively sought addi-
tional markers to use as a test in men with increased 
PSA levels to refine the indication for biopsy.3
Imagine that we wanted to analyze a study of a new 
marker for prostate cancer. The study included 100 
men, all of whom had increased PSA levels with no 
obvious benign cause and were therefore candidates for 
biopsy. We will assume that the results are as for the 
example in the introduction: high grade disease in 25 
patients; when blood samples were analyzed for all 100 
patients, 72 had high levels of the new marker, of whom 
22 had a high grade tumor.
To analyze the study using a net benefit approach, we 
need to define the exchange rate by considering the 
number of men a doctor would biopsy to find one with 
high grade prostate cancer. A urologist might say that 
although it is important to find aggressive cancers early, 
biopsy is uncomfortable and has risks, and most can-
cers can still be caught at a curable stage even if biopsy 
is deferred. One reasonable response would be that to 
find one man with high grade cancer, no more than 10 
men should undergo biopsy. This implies that the harm 
of delaying diagnosis of a high grade cancer is nine 
times greater than that of an unnecessary biopsy (in 10 
men undergoing biopsy, one cancer found equates to 
nine unnecessary biopsies for each cancer detected). So 
in our analysis we want to “weight” finding high grade 
cancer as nine times more important than avoiding 
unnecessary biopsy. Using a similar principle to calcu-
lating profit for importing wine, we can use 1÷9 as the 
exchange rate. We define net benefit as:
Benefit−(harm×exchange rate)The net benefit for carry-
ing out a biopsy in all men is 25%−(75%×(1÷9))=16.7%; 
the net benefit if the marker had been used to determine 
biopsy is 22%−(50%×(1÷9))=16.4%. Because at this par-
ticular exchange rate net benefit is lower for the marker 
than for biopsy in all men, we can conclude that use of 
the marker to determine biopsy would lead to poorer 
clinical outcome than the current practice of biopsy in 
all men with increased PSA levels not clearly due to 
benign disease.
The unit of net benefit is true positives. So a net ben-
efit of 16.4% means that the marker is equivalent to a 
strategy that led to biopsy in 164 men per 1000 at risk, 
with all biopsy results positive for cancer. This is com-
parable to the concept of profit. Leaving aside the prob-
lem of financial risk, a profit of $250 000 for a wine 
transaction is roughly the equivalent of just being 
given $250 000 without having to spend money on buy-
ing wine.
Another similarity between profit and net benefit is 
that the rank order is more important than the size of 
the difference. A wine merchant forced to choose 
between one of two competing trades would choose the 
more profitable one, pretty much irrespective of 
whether profit was higher by $1000 or by $100 000. 
Similarly, we generally choose the strategy with the 
highest net benefit, without worrying about the size of 
the difference in net benefit (though see comments on 
“test harm”).
One obvious criticism of net benefit in such medical 
applications is that the exchange rate is a subjective 
variable. But it is straightforward to vary the exchange 
rate and see how it affects the results. For instance, if a 
doctor is willing to carry out 20 biopsies to find one 
patient with high grade cancer, the net benefit of biopsy 
in all men (that is, 25%−(75%×(1÷19))=21.1%) is still 
higher than that of using the marker (that is, 22%−
(50%×(1÷19))=19.4%).
net benefit and decision curves
We can go one step further by plotting net benefit for a 
wide range of exchange rates. However, to do so, we 
must first bring in an additional idea. One of the ways to 
decide on whether to have a prostate biopsy or not is to 
use a statistical prediction model. This might be based 
on routinely available clinical variables such as age, 
PSA level, and the results of digital rectal examination,2 
but it might also include novel markers.4 The result of 
the model would be expressed in terms of a percentage 
risk of high grade prostate cancer. To determine 
whether the model gives a positive result (high risk, 
biopsy indicated) or a negative result (low risk, biopsy 
not indicated), we need to use a cut point in terms of a 
probability threshold. The key concept is that to be 
 consistent, we need to use the same cut point for the 
statistical model as we do to determine the exchange 
rate between cancers found and unnecessary biopsies. 
A cut point of 10 biopsies for each high grade cancer is 
the equivalent of carrying out a biopsy in men with a 
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risk of ≥10%; if a clinician would be willing to conduct 
as many as 20 biopsies to find a high grade cancer, the 
probability threshold would be 5%.
To see how net benefit varies by different exchange 
rates, we use an algorithm:
1. Choose a threshold probability (pt) to define when a 
patient is positive 
2. Count the number of patients with a positive result 
(risk ≥pt) who have the disease (true positives) versus 
those who have a positive result but are disease-free 
(false positives)
3. With N the total sample size, calculate the net benefit 
(see equation):
4. Repeat steps 2 and 3 for a reasonable range of thresh-
old probabilities.
5. Repeat all steps for each marker, model, or test in the 
study, as well as the “default” strategies of treating all 
men or no men as if the result is positive.
Figure 1  shows a graph obtained from applying this 
algorithm to the marker described above and to a hypo-
thetical statistical prediction model. This type of graph 
is known as a “decision curve”5  and shows the net ben-
efit of the marker and the statistical model as well the 
two clinical alternatives, carrying out a biopsy in all 
men or no men. The first thing to note is the range of 
threshold probabilities on the x axis, which has an 
upper limit of 20% (for illustrative purposes, figure 2 
shows the decision curve across all threshold probabil-
ities). We chose an upper limit of 20% because though 
doctors (taking into account patient preferences) might 
vary in their values for finding cancer compared with 
avoiding unnecessary biopsy, it is unrealistic that any 
doctor or patient would need more than a 20% risk of 
high grade disease before biopsy is recommended. 
Thus the initial step in creating a decision curve 
involves determining a reasonable range of threshold 
probabilities for the specific decision informed by the 
marker, test, or model.
The basic interpretation of a decision curve is that the 
strategy with the highest net benefit at a particular 
threshold probability has the highest clinical value. We 
note that the net benefit for the marker is lower than 
that for the strategy of “biopsy all” for threshold proba-
bilities below about 11%. For the sort of risk averse doc-
tors or patients who have a low threshold probability, 
say 5%, this means that the best clinical outcome—in 
terms of the number of unnecessary biopsies conducted 
and cancers found—would be achieved by conducting 
the biopsy irrespective of the marker results. At a 
threshold of say, 20%, net benefit for the marker is 
higher than for carrying out a biopsy in everyone, so the 
optimal clinical strategy would be to carry out a biopsy 
in only those men positive for the marker. The key point 
is that the marker is only helpful for a subset of prefer-
ences. What we would really like is for the marker to be 
better than any alternative strategy across a wide range 
of reasonable preferences. This is exactly what we see 
for using the statistical model evaluated in the study. 
Owing to slight miscalibration,6 the statistical model is 
worse than just carrying out a biopsy of all men at very 
low threshold probabilities. If we assume that no urolo-
gist would routinely carry out a biopsy in a man with 
less than a 5% risk of high grade cancer, using the 
model to determine whether or not biopsy would lead to 
the best clinical outcomes independent of individual 
preference.
Compare this conclusion from figure 1 with statistics 
such as the sensitivity and specificity of the marker 
(88% and 33%, respectively), the area under the curve 
or Brier score of the model (0.822 and 0.150), or the cal-
ibration plot (see supplementary appendix). It is not at 
all clear how we could know whether the model’s dis-
crimination or calibration was sufficient to justify clini-
cal use.
An example of a decision curve, published in The 
BMJ, concerned external validation of models to predict 
cardiovascular disease in the United Kingdom.7 The 
authors found that the QRISK model, developed on a 
UK population, had a higher net benefit than the well 
established Framingham model. Interestingly, net ben-
efit for Framingham at one widely used cut point was 
zero or negative. This allowed the authors to state that, 
while QRISK was a “useful model” in the UK popula-
tion, Framingham “has no clinical benefit” at some 
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Fig 1 | Decision curve showing net benefit for carrying out 
biopsy in men at risk for aggressive prostate cancer
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Fig 2 | Decision curve as in figure 1 shown for illustrative 
purposes across all threshold probabilities
Net benet    =
True positives − False positives
N N 1–pt
x
pt
Details of equation
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widely used thresholds. (The supplementary appendix 
gives some further examples of decision curves pub-
lished in the recent literature.)
Choice of threshold probabilities
Determining a reasonable range of threshold probabili-
ties is a critical aspect of net benefit approaches. This is 
much simpler than it might seem because the use of a 
range of values means that detailed information about 
any individual’s personal preferences is not needed. All 
we need are general ideas about what might be consid-
ered more or less reasonable. The box gives an example 
of how a doctor might justify the range of thresholds 
(5-20%) used in figure 1. Note that we can derive thresh-
old probabilities by thinking in terms of “numbers 
needed” (that is, how many biopsies would I carry out 
to find one aggressive cancer?). The high and low ends 
of the range are justified in terms of typical patients 
who unquestionably would and would not undergo 
biopsy, and in terms of the risk of side effects. The key 
point is that the investigator does not have to find the 
“correct” threshold, just have an idea of the sort of 
thresholds that would and would not make sense. Note 
also that the doctor in this particular case does not con-
sider financial cost, but another might choose to do so 
(for example, “biopsy is very expensive, so we don’t 
want to do too many to find one cancer”).
What happens if doctors do not have any idea about 
appropriate thresholds, such that an appropriate range 
cannot be determined? Net benefit is a tool for evaluat-
ing the clinical implications of models, markers, and 
tests. A model gives a predicted probability directly; 
markers and tests give positive and negative predictive 
values. If such probabilities cannot be compared 
against some kind of threshold to aid a decision, then 
they have no clinical use and the question of clinical 
evaluation by net benefit is moot.
Another question about threshold probabilities con-
cerns the role of patients. They should generally be 
involved in decision making about their own care, such 
as whether or not to have a biopsy for cancer. However, 
that does not mean that they need to be directly 
involved in considerations of the appropriate range for 
threshold probability in a research study. The range of 
threshold probabilities considered captures differences 
in patient preferences. In the biopsy example, for 
instance, the investigator setting the range thinks about 
patients who “don’t like medical procedures.” Net ben-
efit may take a clinical perspective and incorporate dif-
ferences in preferences between individuals, but the 
research technique gives a result at the population 
level: should doctors use this model, marker, or test in 
their practice?
Extensions to net benefit methods
Net benefit methods are flexible and can be adapted to 
correct for statistical overfit,8  incorporate time to event 
data with and without competing risk,8  and provide 
estimates in terms of the reduction in unnecessary 
interventions.5  Methods have also been published to 
calculate a 95% confidence interval for net benefit8  (see 
supplementary appendix). Net benefit can also incorpo-
rate the harm of a test, such as if an invasive or expen-
sive procedure is required.5 In brief, investigators are 
asked not only about threshold probabilities in the 
usual way but also to specify the maximum number of 
tests they would do to find one true case, assuming that 
the test was perfect. For instance, if a prediction model 
for biopsy of the prostate required magnetic resonance 
imaging, investigators might state that they would do 
no more than about 30 scans to find one high grade can-
cer. The test harm for magnetic resonance imaging 
would then be 0.033 (1/30), and this amount would be 
subtracted from the net benefit of the prediction model 
across all threshold probabilities.
Conclusions
Simple decision analytic approaches can provide a 
clear answer to the question about which of two mod-
els, markers, or tests would lead to better clinical out-
comes on average among suitable patients, and 
whether either would be better than a default strategy 
of treating all patients or none. Net benefit is one such 
decision analytic technique.
Several explanatory papers give further information 
about net benefit9 10 11 12; simple to use software, along 
with tutorials and example data, are available at http://
decisioncurveanalysis.org/. Several similar measures, 
including “relative utility” and “weighted net reclassifi-
cation improvement,” have been proposed that provide 
results consistent with net benefit.13
Net benefit approaches assume that doctors and 
patients will act rationally in accordance with their 
preferences. In the prostate biopsy example, for 
instance, we assume that if a doctor and patient engage 
in shared decision making and decide on a threshold 
probability of 10%, then the patient will indeed undergo 
biopsy if the prediction model gives a probability of 
10% or more but not if the predicted probability is less 
than 10%. The real world of actual clinical practice 
might be somewhat messier, such as if an anxious doc-
tor recommended a biopsy to a patient even though the 
predicted risk turned out to be low. In some cases it can 
be useful to complement net benefit with “impact stud-
ies” that empirically evaluate the effect of a marker, 
model, or test on clinical decision making and patient 
outcomes.14
Urologist discussing a range of threshold probabilities to be used for a decision 
curve in a study of biopsy for prostate cancer
In my own practice, I would not want to do more than 10 biopsies to find one high 
grade prostate cancer, so my own personal threshold is about 10% on average. But 
some of my colleagues are a little more aggressive, and I can imagine them biopsying 
at risks of 6% or 7%. However, I do not think anyone should be biopsied if they have a 
risk less than 5%. This is about the prevalence of high grade disease in 70 year olds, 
and it is not as if we are biopsying almost every 70 year old. Also, the infection rate for 
biopsy is around 4%, and I think your risk of high grade cancer has to be higher than 
your risk of infection. Now at the upper end, I can imagine that some older patients, or 
those who do not like medical procedures, might have a higher threshold, something 
like 15%. But I can’t imagine many patients refusing a biopsy if they had more than a 
20% risk of high grade cancer: that’s about the risk of someone with a PSA of 25 ng/
mL, which is normally seen as being pretty much off the charts
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Although this decision analytic approach is relatively 
novel, net benefit is increasingly used in practical appli-
cations, including high profile publications such as The 
BMJ.7 Given that the purpose of statistical analysis is 
often to help doctors make better decisions, wider use 
of net benefit, a sound decision analytic technique, will 
better match the clinical aim of much medical research. 
We advocate reporting net benefit alongside measures 
of discrimination and calibration to provide a statistic 
of immediate clinical interpretability.
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